Cybin Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.316
- Today's High:
- $0.3299
- Open Price:
- $0.3269
- 52W Low:
- $0.21
- 52W High:
- $1.14
- Prev. Close:
- $0.33
- Volume:
- 1238203
Company Statistics
- Market Cap.:
- $52.20 million
- Book Value:
- 0.295
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-311000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -43.43%
- Return on Equity TTM:
- -71.33%
Company Profile
Cybin Inc had its IPO on 2019-09-13 under the ticker symbol CYBN.
The company operates in the Healthcare sector and Biotechnology industry. Cybin Inc has a staff strength of 50 employees.
Stock update
Shares of Cybin Inc opened at $0.33 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.32 - $0.33, and closed at $0.33.
This is a -0.03% slip from the previous day's closing price.
A total volume of 1,238,203 shares were traded at the close of the day’s session.
In the last one week, shares of Cybin Inc have increased by +6.08%.
Cybin Inc's Key Ratios
Cybin Inc has a market cap of $52.20 million, indicating a price to book ratio of 1.1616 and a price to sales ratio of 278.2498.
In the last 12-months Cybin Inc’s revenue was $0 with a gross profit of $-311000 and an EBITDA of $-53938000. The EBITDA ratio measures Cybin Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cybin Inc’s operating margin was 0% while its return on assets stood at -43.43% with a return of equity of -71.33%.
In Q4, Cybin Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cybin Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.21 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cybin Inc’s profitability.
Cybin Inc stock is trading at a EV to sales ratio of 313.5883 and a EV to EBITDA ratio of -0.357. Its price to sales ratio in the trailing 12-months stood at 278.2498.
Cybin Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $60.69 million
- Total Liabilities
- $4.37 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $207000
- Dividend Payout Ratio
- 0%
Cybin Inc ended 2024 with $60.69 million in total assets and $0 in total liabilities. Its intangible assets were valued at $60.69 million while shareholder equity stood at $56.33 million.
Cybin Inc ended 2024 with $0 in deferred long-term liabilities, $4.37 million in other current liabilities, 153017000.00 in common stock, $-134431000.00 in retained earnings and $24.81 million in goodwill. Its cash balance stood at $22.51 million and cash and short-term investments were $22.64 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Cybin Inc’s total current assets stands at $30.11 million while long-term investments were $0.00 and short-term investments were $125000.00. Its net receivables were $2.60 million compared to accounts payable of $4.37 million and inventory worth $0.
In 2024, Cybin Inc's operating cash flow was $0 while its capital expenditure stood at $207000.
Comparatively, Cybin Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.33
- 52-Week High
- $1.14
- 52-Week Low
- $0.21
- Analyst Target Price
- $4.38
Cybin Inc stock is currently trading at $0.33 per share. It touched a 52-week high of $1.14 and a 52-week low of $1.14. Analysts tracking the stock have a 12-month average target price of $4.38.
Its 50-day moving average was $0.37 and 200-day moving average was $0.37 The short ratio stood at 2.73 indicating a short percent outstanding of 0%.
Around 2228.5% of the company’s stock are held by insiders while 786.4% are held by institutions.
Frequently Asked Questions About Cybin Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.